GoldenGolden
Immusoft

Immusoft

Immusoft is a biotechnology company developing a platform for the insertion of therapeutic genes into immune cells for the treatment of a variety of genetic diseases.

Immusoft is developing an approach to sustained delivery of protein therapeutics using a patient's own cells. The approach is called Immune System Programming (ISPTM). ISP entails collecting a type of the patient's immune cells, called B cells. In response to immune stimulation, B cells can turn into a biofactory state known as a plasma cell. Plasma cells manufacture and secrete thousands of antibodies per second. We harness this biofactory capability of the plasma cell by programming B cells to produce a given protein therapeutics.

Timeline

September 2020
Immusoft raises a $467,000 grant from National Institutes of Health.
September 2020
Immusoft raises a $467,000 grant from National Institutes of Health.
September 2020
Immusoft raises a $4,500,000 venture round from Breakout Ventures, Ikarian Capital Llc and Mesa Verde Venture Partners.
September 2020
Immusoft raises a $4,500,000 venture round from Breakout Ventures, Ikarian Capital Llc and Mesa Verde Venture Partners.
January 2019
Immusoft raises a $20,000,000 series B round from Breakout Ventures, DEFTA Partners, Mesa Verde Venture Partners and RBV Capital.
September 2018
Immusoft raises a $3,500,000 grant from National Institute of General Medical Science.
September 2018
Immusoft raises a $3,500,000 grant from National Institute of General Medical Science.
January 2018
Immusoft raises a $3,000,000 series B round from 600 Mile Challenge Fund.
November 2016
Immusoft raises a $2,700,000 series A round from Breakout Ventures, FF Science, Propel(x) and Technium Partners.
November 2016
Immusoft raises a $2,700,000 series A round from Breakout Ventures, FF Science, Propel(x) and Technium Partners.
Page 1 of 2

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Immusoft Series A round, November 2016
2,700,000
November 2016
14 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Cam Gallagher

Chief Business Officer

Jason Fontenot

Chief Scientific Officer

Monika Swietlicka

Vice President of Regulatory Affairs

Scott McIvor

Chief Development Officer

Sean Ainsworth

Chief Executive Officer

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.